[go: up one dir, main page]

WO2005063807A3 - Treatment of coronary or peripheral ischemia - Google Patents

Treatment of coronary or peripheral ischemia Download PDF

Info

Publication number
WO2005063807A3
WO2005063807A3 PCT/EP2004/014910 EP2004014910W WO2005063807A3 WO 2005063807 A3 WO2005063807 A3 WO 2005063807A3 EP 2004014910 W EP2004014910 W EP 2004014910W WO 2005063807 A3 WO2005063807 A3 WO 2005063807A3
Authority
WO
WIPO (PCT)
Prior art keywords
coronary
treatment
product
relates
peripheral ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/014910
Other languages
French (fr)
Other versions
WO2005063807A2 (en
Inventor
Andre Uzan
Alexis Caron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Centelion SAS
Original Assignee
Aventis Pharma SA
Centelion SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA, Centelion SAS filed Critical Aventis Pharma SA
Priority to AU2004309090A priority Critical patent/AU2004309090A1/en
Priority to MXPA06007519A priority patent/MXPA06007519A/en
Priority to EP04804488A priority patent/EP1699819A2/en
Priority to JP2006546135A priority patent/JP2007536909A/en
Priority to CA002550727A priority patent/CA2550727A1/en
Publication of WO2005063807A2 publication Critical patent/WO2005063807A2/en
Publication of WO2005063807A3 publication Critical patent/WO2005063807A3/en
Priority to IL176401A priority patent/IL176401A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to novel methods of treating a patient having peripheral and/or coronary ischemic syndrome and also relates to a product comprising an expression vector encoding an angiogenic growth factor and a heparin compound, wherein the product is capable of acting in a synergistic manner to promote angiogenesis and arteriogenesis in skeletal and cardiac muscles.
PCT/EP2004/014910 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia Ceased WO2005063807A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004309090A AU2004309090A1 (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia
MXPA06007519A MXPA06007519A (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia.
EP04804488A EP1699819A2 (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia
JP2006546135A JP2007536909A (en) 2003-12-29 2004-12-29 Treatment of coronary artery or peripheral ischemia
CA002550727A CA2550727A1 (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia
IL176401A IL176401A0 (en) 2004-12-29 2006-06-19 Treatment of coronary or peripheral ischemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53299303P 2003-12-29 2003-12-29
US60/532,993 2003-12-29

Publications (2)

Publication Number Publication Date
WO2005063807A2 WO2005063807A2 (en) 2005-07-14
WO2005063807A3 true WO2005063807A3 (en) 2005-09-29

Family

ID=34738851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/014910 Ceased WO2005063807A2 (en) 2003-12-29 2004-12-29 Treatment of coronary or peripheral ischemia

Country Status (8)

Country Link
EP (1) EP1699819A2 (en)
JP (1) JP2007536909A (en)
KR (1) KR20070006714A (en)
AU (1) AU2004309090A1 (en)
CA (1) CA2550727A1 (en)
MX (1) MXPA06007519A (en)
WO (1) WO2005063807A2 (en)
ZA (1) ZA200606268B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010116271A (en) * 2007-09-26 2011-11-10 Селджин Селльюлар Терапьютикс (Us) ANGIOGENIC CELLS FROM HUMAN PLACENTAL PERFUSAT
EP2558115B1 (en) * 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
CN105828833A (en) 2013-10-21 2016-08-03 萨克生物研究学院 Mutated fibroblast growth factor (fgf) 1 and methods of use
EP3368059A4 (en) 2015-10-30 2019-03-27 Salk Institute for Biological Studies TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) ANALOGUES 1
TWI698241B (en) * 2017-09-05 2020-07-11 國立成功大學 Heparin composition for treating ischemia
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
WO1998036075A1 (en) * 1997-02-14 1998-08-20 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and related aspects thereof
WO2001040267A2 (en) * 1999-12-05 2001-06-07 Yeda Research And Development Co. Ltd. Proteoglycans and pharmaceutical compositions comprising them
WO2003038054A2 (en) * 2001-10-31 2003-05-08 New York University Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
US20040115769A1 (en) * 1998-07-24 2004-06-17 Stegmann Thomas J. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
WO2004108167A1 (en) * 2003-06-05 2004-12-16 Gencell Sas Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998036075A1 (en) * 1997-02-14 1998-08-20 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and related aspects thereof
US20040115769A1 (en) * 1998-07-24 2004-06-17 Stegmann Thomas J. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
WO2001040267A2 (en) * 1999-12-05 2001-06-07 Yeda Research And Development Co. Ltd. Proteoglycans and pharmaceutical compositions comprising them
WO2003038054A2 (en) * 2001-10-31 2003-05-08 New York University Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
WO2004108167A1 (en) * 2003-06-05 2004-12-16 Gencell Sas Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOMBARDINI T, PICANO E, ANGIOLOGY, vol. 48, no. 11, 1997, 1997, XP009048360 *
CHINEN N ET AL: "Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize bFGF and induce angiogenesis by controlling its release", J BOMED MATER RES A, vol. 67, no. 1, 1 October 2003 (2003-10-01), pages 61 - 68, XP002330650 *
FUJITA M ET AL: "Comparative effect of heparin treatment with and without strnuous exercise on treadmill capacity in patients with stable effort angina", AM HEART J., vol. 122, no. 2, August 1991 (1991-08-01), pages 453 - 457, XP009048392 *
NABEL E G ET AL: "Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo", NATURE, vol. 362, no. 6423, 1993, 29-04-1993, pages 844 - 846, XP002913600 *
ROSENGART T K ET AL: "THERAPEUTIC ANGIOGENESIS: A COMPARATIVE STUDY OF THE ANGIOGENIC POTENTIAL OF ACIDIC FIBROBLAST GROWTH FACTOR AND HEPARIN", JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, vol. 26, no. 2, 1997, pages 302 - 312, XP009037933, ISSN: 0741-5214 *
SAFI J ET AL: "Gene Therapy with Angiogenic Factors: A new Potential Approach to the Treatment of Ischemic Diseases", J MOL CELL CARDIOL, vol. 29, 1997, pages 2311 - 2325, XP002330651 *
UCHIDA Y ET AL: "Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC., ST. LOUIS, MO, US, vol. 130, no. 6, December 1995 (1995-12-01), pages 1182 - 1188, XP004528736, ISSN: 0002-8703 *

Also Published As

Publication number Publication date
WO2005063807A2 (en) 2005-07-14
KR20070006714A (en) 2007-01-11
CA2550727A1 (en) 2005-07-14
EP1699819A2 (en) 2006-09-13
JP2007536909A (en) 2007-12-20
MXPA06007519A (en) 2007-05-23
ZA200606268B (en) 2008-04-30
AU2004309090A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
MY134641A (en) Indolinephenylsulphonamide derivatives
BR0107241A (en) Compounds, process of preparation of compounds, use of compounds, fungicidal compositions, process of preventive or curative control of plant pathogenic fungi of the cultures and method of preventive or curative treatment of construction wood
EE04854B1 (en) Oxabispidine Compounds, Methods and Formulations thereof for use in the treatment and prophylaxis of cardiac arrhythmias
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
NO20003233L (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antivirals
MXPA02002118A (en) Compositions containing legume products.
WO2003059258A3 (en) Compositions and methods for treating heart failure
WO2005063807A3 (en) Treatment of coronary or peripheral ischemia
WO2003037259A3 (en) Methods for the prevention or treatment of bacterial and fungal infections
WO2003057820A3 (en) Peptide activators of vegf
EP1236465A3 (en) Use of legume products for the treatment of external aggressions
UA86400C2 (en) Normal;heading 1;heading 2;USE OF LOW-DOSE ERYTHROPOIETIN FOR PATIENTS WITH DYSFUNCTION OF ENDOTHELIAL PRECURSOR CELLS, CARDIOVASCULAR RISK FACTOR AND END ORGAN DAMAGES
MXPA02002119A (en) Legume products.
SE0100326D0 (en) New compounds
WO2003059265A3 (en) Compositions and methods for treating heart failure
ATE427107T1 (en) A NEW USE OF DEFERIPRONE
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
TW200628451A (en) Novel pyrimidine derivatives and their use
MXPA02008213A (en) Substituted piperazine compounds.
WO2003000009A3 (en) Stimulation of vascularization with vegf-b
NO20000016L (en) Cyclic azapeptides with angiogenic activity
EP1236402A3 (en) Compositions containing legume products
EE200300506A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
WO2004037167A3 (en) Methods of treating dry eye disease with lantibiotics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004804488

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 176401

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2550727

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006546135

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/007519

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004309090

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067015154

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006/06268

Country of ref document: ZA

Ref document number: 200606268

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2004309090

Country of ref document: AU

Date of ref document: 20041229

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004309090

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004804488

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067015154

Country of ref document: KR